Peripheral blood mononuclear cells (PBMCs) were isolated from blood filters and fresh blood from healthy donors. PBMCs were incubated in medium with 1% fetal bovine serum without or with RV001 for 12, 24, or 48 hours. PBMCs were stained with tagged antibodies, washed, and fixed in 1% paraformaldehyde. They were analyzed by flow cytometry for IGF-1R display on CD4+ T cells and CD14+ monocytes.

Our results demonstrate that RV001 decreases IGF-1R levels on CD4+ T cells and CD14+ monocytes from healthy donors. Previous studies have shown that IGF-1R might be an autoantigen in Graves' orbitopathy: activating anti-IGF-1R antibodies may promote cellular responses such as T and B cell migration and survival, and hyaluronan synthesis in orbital fibroblasts. Furthermore, IGF-1R and TSHR form a physical and functional complex. RV001 is a promising therapy that may be effective in mitigating Graves' orbitopathy by blocking the IGF-1R/TSHR inflammatory pathways.